Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597462 | 1.00 | GSK3B (0.42) | GSK3BGSK3AMAPTPKMSMN1; SMN2 | |
| SCHEMBL4597466 | 1.00 | GSK3B (0.42) | GSK3BGSK3AMAPTPKMSMN1; SMN2 | |
| SCHEMBL4598169 | 0.84 | BRD4 (0.42) | MAPTPKMSMN1; SMN2BRD4ALDH1A1 | |
| SCHEMBL4598167 | 0.84 | BRD4 (0.42) | MAPTPKMSMN1; SMN2BRD4ALDH1A1 | |
| SCHEMBL4596729 | 0.76 | SLC18A3 (0.36) | MAPTSMN1; SMN2BRD4 | |
| SCHEMBL4596732 | 0.76 | SLC18A3 (0.36) | MAPTSMN1; SMN2BRD4 | |
| SCHEMBL4598206 | 0.76 | SLC18A3 (0.38) | SMN1; SMN2BRD4 | |
| SCHEMBL4598200 | 0.76 | SLC18A3 (0.38) | SMN1; SMN2BRD4 | |
| SCHEMBL4598197 | 0.76 | SLC18A3 (0.38) | SMN1; SMN2BRD4 | |
| SCHEMBL5576661 | 0.73 | CCR5 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924265-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | Genzyme Corporation (US) | 2008-05-28 | — | — | EP | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
| WO-2007022371-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | GSK3B 765/4885GSK3A 861/4885MAPT 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.